Table 3.
TLR4 agonist LPS treatment blocks the protection of Sev on cardiac dysfunction.
| Index | Time | Sev + I/R + DMSO group | Sev + I/R + LPS group |
|---|---|---|---|
| HR (beat/min) | T0 | 162.24 ± 12.23 | 157.68 ± 12.59 |
| T4 | 125.24 ± 9.65 | 101.27 ± 9.24 | |
| LVDP (mmHg) | T0 | 119.06 ± 10.32 | 112.69 ± 10.55 |
| T4 | 68.69 ± 7.73 | 41.62 ± 3.11 | |
| LVEDP (mmHg) | T0 | 9.44 ± 1.25 | 8.24 ± 0.97 |
| T4 | 31.27 ± 3.54 | 42.32 ± 4.17 | |
| dp/dtmax(+)(mmHg/s) | T0 | 2971.81 ± 301.36 | 2937.87 ± 225.49 |
| T4 | 1622.03 ± 153.17 | 1201.15 ± 98.44 | |
| dp/dtmax(-)(mmHg/s) | T0 | 2302.06 ± 200.64 | 2288.61 ± 154.37 |
| T4 | 967.76 ± 93.37 | 489.57 ± 28.95 |
Note: Sev, Sevoflurane; IRI, ischemia/reperfusion injury; HR, heart rate; LVEDP, left ventricular end-diastolic pressure; LPS, lipopolysaccharide; DMSO, dimethylsulfoxide; LVDP, left ventricular developmental pressure; dp/dtmax (+), maximum rate of rise of left ventricular pressure; dp/dtmax (-), maximum rate of decline of the left ventricular pressure.